Maintenance prophylactic treatment of asthma in patients 5 yr of age and older; asthma patients requiring systemic corticosteroid administration in which adding an inhaled corticosteroid may reduce or eliminate need for systemic corticosteroids.
Seasonal allergic or perennial rhinitis.
Prevention of recurrence of nasal polyps following surgical removal.
Maintenance treatment of asthma as prophylactic therapy.
May decrease requirement for or eliminate use of systemic corticosteroids in patients with asthma.
Adults and children 12 yr of age and older:PO Oral inhalation If previous therapy consisted of bronchodilators alone, start with 40 or 80 mcg twice daily (max dose, 320 mcg twice daily); if previous therapy consisted of inhaled corticosteroids, start with 40 to 160 mcg twice daily (max dose, 320 mcg twice daily).
Children 5 to 11 yr of age:PO Oral inhalation If previous therapy consisted of bronchodilators alone or inhaled corticosteroids, start with 40 mcg twice daily (max dose, 80 mcg twice daily).
Nasopharyngeal irritation (24%); sneezing attacks (4%); nasal stuffiness, nosebleeds, rhinorrhea, tearing eyes (less than 3%); dryness, irritation of the nose and throat, unpleasant taste and smell. GI:
Nausea (at least 3%).
Nausea (less than 5%). GU:
Dysmenorrhea (1% to 3%). METAB: Suppression of hypothalamic-pituitary-adrenal (HPA) function. RESP:
Increased asthma symptoms, upper respiratory tract infections (at least 3%); coughing (1% to 3%). OTHER: Growth velocity reduction in children; rare cases of immediate and delayed hypersensitivity reaction with angioedema, bronchospasm, rash, and urticaria; weight gain.
Back pain, dysphonia, oral symptoms, pain (at least 3%).
Absorption: 20%. Action is primarily local following inhalation.
Distribution: Crosses the placenta and enters breast milk in small amounts.
Metabolism/Excretion: Following inhalation, beclomethasone dipropionate is primarily converted to beclomethasone 17–monopropionate (active metabolite); primarily excreted in feces (<10% excreted in urine).